This clinical trial is focused on studying Moderate-Severe Atopic Dermatitis, a skin condition that causes red, itchy, and inflamed skin. The study will test two investigational treatments, known by their code names PF-07275315 and PF-07264660, both developed by Pfizer Inc. These treatments are biologic medications, which means they are made from proteins and other substances found in living organisms. The purpose of the study is to evaluate how effective and safe these treatments are compared to a placebo in adults with moderate to severe atopic dermatitis.

Participants in the study will be randomly assigned to receive either one of the investigational treatments or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are not biased. The study will last for several weeks, during which participants will have regular check-ups to monitor their skin condition and overall health. The main goal is to see if there is a significant improvement in the skin condition, measured by a tool called the Eczema Area and Severity Index (EASI), which assesses the extent and severity of eczema.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The researchers will also track any changes in vital signs, such as heart rate and blood pressure, as well as results from laboratory tests. The study aims to provide valuable information on whether these new treatments can offer a safe and effective option for people suffering from moderate to severe atopic dermatitis.